During COMy 2020, Enrique Ocio, Marqués de Valdecilla University Hospital, Santander, ES, spoke to the Multiple Myeloma (MM) Hub about resistance mechanisms to current standard of care and how to overcome them.

Although advances in treatment options for MM have improved the outcome of patients in recent years, resistance remains a problem and MM is still considered an incurable disease. Here, Enrique Ocio discusses the importance of understanding the mechanisms behind both primary and secondary resistance in order to overcome them.

Hosted on Acast. See acast.com/privacy for more information.

During COMy 2020, Artur Jurczyszyn, Jagiellonian University Medical College, Krakow, PL, spoke to the Multiple Myeloma Hub. We asked: What is plasma cell leukemia and what are the latest advances in treatment?

In this podcast, Artur Jurczyszyn talks about the classifications of plasma cell leukemia and the importance of outlining a plasma cell prognostic index for use in clinical practice. The data from two retrospective analyses, evaluating primary and secondary plasma cell leukemia, are discussed.

Hosted on Acast. See acast.com/privacy for more information.